heading · body

Earnings · NUVAMA · Financials / Wealth & Capital Markets

Nuvama Wealth — a PAG-built wealth platform compounding through a flat patch

Nuvama Wealth Management Limited

period Q1 FY26 → Q4 FY26 added 2026-06-11 score 7/10
earnings-call financials NUVAMA india

The Pulse

Nuvama is the former Edelweiss Securities, carved out and listed in 2023 under the control of the private-equity firm PAG, and it has become one of India’s larger wealth-and-capital-markets platforms — roughly ₹4.5 lakh crore of client assets, ₹3,100 crore of revenue, and operating profit that crossed ₹1,000 crore for the first time in FY26 at a ~28% return on equity. The franchise is genuinely good and the long-term story — under-penetrated Indian wealth management — is real. But the present tense is a plateau: quarterly profit has sat flat around ₹250-270 crore for six straight quarters, and full-year FY26 profit grew only ~6%. Management’s defence is that the composition is improving faster than the headline — recurring, fee-based wealth income now dominates, which makes earnings more predictable even when capital markets are soft. The things to keep in view: a high-quality, diversified platform with deepening recurring revenue; offset by a cyclical capital-markets arm, a PE owner with most of its stake pledged, and a demanding ~26x multiple on currently-stalled earnings.

The Business

Nuvama makes money four ways, and the mix is the whole point. Wealth Management — advising affluent and HNI clients, increasingly through managed products (its “MPIS” book) that pay a recurring fee — is the largest and fastest-compounding engine. Private (the UHNI arm) serves the very top of the pyramid with over ₹54,000 crore of recurring-fee assets. Asset Management is the smallest and still sub-scale — only recently profitable, with new alternatives and mutual-fund products being seeded. Asset Services provides custody and clearing to institutions (this is where Jane Street was a client). And Capital Markets — institutional equities plus investment banking, where Nuvama is among the top IPO bankers — is the highest-beta piece, lumpy and cycle-dependent.

The legal core is a broking and securities house: it carries a large securities-financing book (~₹11,500 crore of borrowings funding client lending), which is why its return on equity (~27%) sits well above its return on capital (~17.5%) — leverage, used normally for a financier, amplifies the returns. The genuine edge is the integrated, full-stack platform: a single relationship can be monetised across broking, lending, managed products, custody and banking — “full wallet share” — supported by a unified technology stack (Nuvama One, MARS) that lets relationship managers scale. The moat, though, is relationship- and talent-based rather than structural: the whole machine runs on relationship managers, and CEO Ashish Kehair pointedly warned his own RMs about new entrants dangling “stratospheric” valuation-linked offers to poach them. The controlling shareholder is PAGAC Ecstasy (the PAG vehicle), at ~54%.

How Management Thinks

Kehair and CFO Bharat Kalsi are precise, confident communicators who run a consistent playbook: “don’t read the quarter, read the trend.” When pressed on flat absolute profit, they steer every time to the composition shift — wealth and private now ~57% of revenue (up from ~47% a year earlier), recurring revenue rising toward 55%, and a multi-year thesis that Indian wealth penetration grows many-fold over a decade as unorganised players cede share. On that strategic spine they are credible and have largely delivered the product build-out they promised: mutual-fund and SIF licences, a CRE fund, private credit, RTA and trusteeship subsidiaries — each broadly arriving on the timelines they set.

Their candour is a genuine strength. They volunteered the Jane Street regulatory episode’s exact impact on asset services (a one-to-two-quarter dent, capped institutional-equities PAT at ₹15-20 crore, back to run-rate by autumn), disclosed lost clients and attrition, owned a one-time labour-code provision, and admitted that the hoped-for migration of transactional clients to recurring ARR “is not happening yet.” That willingness to name the warts is reassuring in a sector prone to spin.

Capital allocation is where the read gets more mixed. As a newly listed, PAG-controlled entity, Nuvama flipped from paying zero dividends (while building the listed structure) to a ~50% payout almost overnight — a classic private-equity harvest, defensible at a 27% ROE but worth recognising for what it is. There is no buyback. Capital that is retained goes into the lending book, AMC seeding, offshore expansion and M&A optionality — sensible reinvestment. The flags sit on the ownership: roughly 63% of the promoter (PAG) holding is pledged, and a PE sponsor will eventually look to exit, an overhang the market has to discount. Layered on top is the unresolved Anugrah/NCSL clearing-account litigation — a lien of roughly ₹4,600 crore, around half a year’s profit, which management assesses as remote and has not provided for, but which the Supreme Court has now admitted.

Where It’s Going

The forward story is a bet that the recurring-revenue machine keeps compounding through the cycle while the new products mature into a second leg. Management guides to net new money of roughly ₹19-20,000 crore in FY26 rising toward ₹25-26,000 crore in FY27, steady ~100bps-a-year cost-to-income improvement, and fixed-income/asset-management lines compounding at 20%-plus. The asset-services yield has been re-based higher (toward 2.6-2.9% on a better collateral mix) after the Jane Street disruption, and the AMC is finally adding fee-paying scale.

The tensions are clear-eyed. The headline profit has stalled, and the reacceleration depends partly on capital markets — broking and investment banking — recovering, which is cyclical and outside management’s control; a genuine market downturn would hit the highest-margin transactional lines hardest. The recurring-revenue shift is the right structural hedge against exactly that, but it is still a work in progress (the ARR migration “not happening yet” admission matters). And the equity-story overhangs — the PAG pledge and eventual exit, the Anugrah tail risk — are the kind of things that cap a multiple regardless of operating performance.

The Four Checks

  1. Quality & moat (gate) — 6/10. A good franchise without a deep moat. The integrated full-stack platform creates real wallet-share stickiness and the wealth/private books have switching friction and trusted-advisor lock-in; the recurring-fee shift improves durability. But it is contestable — Indian wealth is a crowded, fast-growing field (360 One, banks, new well-funded entrants), the model is talent-dependent (RMs are poachable, by management’s own admission), and the capital-markets arm is plainly cyclical and commoditising. Decent edge, not unassailable.

  2. Returns on incremental capital & runway — 6/10. ROE of ~27-28% is attractive and the structural runway — low Indian wealth penetration — is long and real. Two things hold the score at 6: the returns are leverage-amplified (ROE well above the ~17.5% ROCE, on a large financing book), and the recent reinvestment results have stalled (FY26 PAT +6%, profit flat for six quarters) while half the earnings are paid out rather than compounded — so the engine is good but not currently demonstrating the high-return reinvestment a top score needs.

  3. Capital allocation for the stage — 6/10. Reasonable, with caveats. The 40-60% dividend policy is sensible at this ROE and retained capital is deployed rationally into lending, AMC seeding and adjacencies; no value-destructive buyback at a rich multiple. But the abrupt zero-to-50% payout flip reads as a PE harvest, and the ~63% promoter-stake pledge plus the eventual PAG exit are real capital-structure overhangs that a cleaner owner wouldn’t carry. Competent, but shaped by the sponsor’s agenda as much as the business’s.

  4. Price — 4/10. Demanding. At ~26x earnings and ~6.7x book for a business whose profit grew ~6% last year, the multiple is pricing the structural wealth-growth story, not the current run-rate. Capital-markets cyclicality, the Anugrah litigation tail, and the PAG overhang all argue for a discount the price doesn’t offer. Quality is real; the margin of safety is thin.

Engine score: 18/30 (moat 6 + reinvestment 6 + allocation 6). A high-quality, diversified wealth-and-markets platform compounding through a flat patch, with the recurring-revenue shift its best feature and a cyclical arm plus PE-sponsor overhangs its main limits. Price (4) leaves little room for disappointment.

Sources

  • Concall transcripts read: Q1 FY26 (14 Aug 2025), Q2 FY26 (5 Nov 2025), Q3 FY26 (27 Jan 2026), Q4 & FY26 (12 May 2026).
  • Annual reports read: FY25, FY24. Both AR section-extracts were thin — no Chairman/CEO letter or MD&A prose survived extraction (Nuvama’s narrative lives in integrated-report pages that didn’t convert), so strategy and forward colour lean heavily on the concalls; segment, ownership and dividend data came through.
  • Snapshot: screener.in consolidated, fetched 11 Jun 2026 (logged-out public session).
  • Gaps / caveats: AUM/wallet-share figures absent from the ARs; the ~₹4,600 cr Anugrah/NCSL lien is unprovided (management deems it remote); ~63% of promoter holding is pledged (screener-flagged). Some transcript analyst-name attribution noise was noted by the agents but didn’t affect substance. Research dumps in vault/Sources/Earnings/Nuvama Wealth Management Ltd/.